Treatment of endogenous uveitis with anti-CD4 monoclonal antibody: first report.
A patient with endogenous uveitis was treated with a chimeric monoclonal anti-CD4 antibody. This patient with long-standing therapy-refractive uveitis did not benefit immediately from antibody infusions, although the frequency of uveitis relapses was sharply reduced after this therapy. After treatment with the monoclonal antibody, this patient's response to conventional immunosuppression improved. The patient had very low CD4+ T-cell counts before the beginning of antibody therapy. In this case, peripheral T-cell counts slowly increased. Antigen-specific T-cell responses to retinal S-antigen in this patient were significantly elevated only just prior to a clinical relapse. The initially high level of spontaneous T-cell proliferation normalized after antibody infusions.
Thurau
S R
SR
University Eye Hospital, Section of Immunology, Munich, Germany.
Wildner
G
G
Reiter
C
C
Riethmüller
G
G
Lund
O E
OE
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000941:Antigens / Q000276:immunology; D019393:Arrestin; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D004359:Drug Therapy, Combination; D005136:Eye Proteins / Q000276:immunology; D006801:Humans; D007262:Infusions, Intravenous; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D013601:T-Lymphocytes / Q000276:immunology; D014605:Uveitis / Q000188:drug therapy*; D014792:Visual Acuity
D000911:Antibodies, Monoclonal; D000941:Antigens; D019393:Arrestin; D005136:Eye Proteins; D011993:Recombinant Fusion Proteins; D011239:Prednisolone